AstraZeneca Canada Inc. expands product portfolio to include vaccines
AstraZeneca Canada Inc. announced that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza Vaccine, Live Attenuated Intranasal) with Health Canada. Working in partnership with its biologics subsidiary MedImmune, AstraZeneca Canada intends to bring MedImmune's vaccine technology to Canadian patients through its FluMist product, which is administered intranasally. The proposed indication for FluMist is for the prevention of seasonal influenza.
The submission is based on data from 73 global clinical and U.S. post-marketing studies of more than 141,000 subjects ranging in age from seven weeks to 97 years and conducted in 38 countries. During the 2004 to 2005 flu season, a large study was completed comparing FluMist, administered as a mist sprayed into the nose, to the injectable flu shot. The study included more than 8,000 children, of which more than 4,000 were between two to five years of age and showed that the group of children who received FluMist had significantly fewer cases of flu than the group who received the injectable flu shot.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.